AquaBounty Technologies, Inc. (NASDAQ:AQB) Sees Large Decrease in Short Interest

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the target of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 9,108 shares, a decline of 47.4% from the January 29th total of 17,318 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 34,098 shares, the short-interest ratio is presently 0.3 days. Based on an average daily trading volume, of 34,098 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AquaBounty Technologies in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in AquaBounty Technologies stock. Renaissance Technologies LLC lifted its stake in shares of AquaBounty Technologies, Inc. (NASDAQ:AQB) by 311.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 121,585 shares of the company’s stock after buying an additional 92,065 shares during the period. Renaissance Technologies LLC owned about 3.14% of AquaBounty Technologies worth $113,000 as of its most recent SEC filing. 8.92% of the stock is owned by hedge funds and other institutional investors.

AquaBounty Technologies Price Performance

NASDAQ AQB opened at $0.97 on Friday. The business has a fifty day moving average price of $0.93 and a two-hundred day moving average price of $1.14. The stock has a market capitalization of $3.76 million, a PE ratio of -1.17 and a beta of 1.28. AquaBounty Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $2.95.

About AquaBounty Technologies

AquaBounty Technologies, Inc is a biotechnology company focused on aquaculture innovation through the development and commercialization of genetically engineered fish. Its flagship product, AquAdvantage Salmon, is an Atlantic salmon strain enhanced with a growth hormone gene that enables faster growth and more efficient feed conversion compared with conventional farmed salmon. By integrating biotechnology into seafood production, AquaBounty aims to address global protein demand while reducing the environmental footprint associated with marine aquaculture.

Founded in 1991, AquaBounty is headquartered in Maynard, Massachusetts, and operates a state-of-the-art, land-based incubation and grow-out facility in Panama.